Lebel, E., Abdulgawad, A., Bramanti, S., Garate, G., Ho, P., Keränen, M., Cohen, Y., Vase, M., Khot, A., Kristensen, I., Leblanc, R., Lee, C., Legiec, W., Magen, H., Mateos, M., Oh, D., Pour, L., Schutz, N., Spyridonidis, A., Weisel, K., Zaucha, J., Larson, S., Varshavsky-Yanovsky, A., Grazioli, K., Basudhar, D., Hu, H., Meng, Y., Eldjerou, L., Bal, S., Harrison, S., Popat, R., Raab, M. and Rodriguez-Otero, P. (2026) “P58 | TRIAL IN PROGRESS: QUINTESSENTIAL-2 – A PHASE 3 STUDY OF ARLOCABTAGENE AUTOLEUCEL VS. STANDARD OF CARE IN ADULT PATIENTS WITH RELAPSED AND REFRACTORY MULTIPLE MYELOMA EXPOSED TO LENALIDOMIDE”, Haematologica. Pavia, Italy, 111(s2). doi: 10.3324/haematol.2026.s2.14111.